Alteration of the miR-let-7c:Lin28 ratio as a predictor of therapy resistance in Prostate Cancer
Alteration of the miR-let-7c:Lin28 ratio as a predictor of therapy resistance in Prostate Cancer
批准号:
9568711
负责人:
Nagalakshmi Nadiminty
金额:
$7.68万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-22 至 2020-08-31
关键词:
AmericanAndrogen AntagonistsAntiandrogen TherapyBindingBiologicalBiological AssayBiological MarkersBloodBlood specimenCancer EtiologyCastrationCell CycleCell divisionClinicClinicalDataDetectionDevelopmentDiseaseEnvironmentExhibitsExpression ProfilingFDA approvedFamilyFeedbackFutureGene ExpressionGenerationsGenesGenomicsHMGA2 geneHumanIncidenceLeadLocationMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMeasurementMeasuresMessenger RNAMicroRNAsMusOncogenesPatient CarePatient-Focused OutcomesPatientsPhysiciansPlasmaProstatePublic HealthRNARNA-Binding ProteinsRegulationRepressionResearch PersonnelResearch ProposalsResistanceResistance developmentRisk AssessmentSamplingScreening for Prostate CancerSpecificityStem Cell FactorTestingThe University of California Davis Clinical Cancer CenterTherapeuticTimeTreatment EfficacyTumor Suppressor ProteinsTumor-DerivedUrineXenograft procedureandrogen deprivation therapyanticancer researchbiobankbiomarker identificationcancer cellcancer therapychemotherapycohorteffective therapyembryonic stem cellexosomeextracellularhuman studyimprovedinnovationmembermenmolecular markermortalitynext generationnovel diagnosticsoutcome forecastoverexpressionprognostic toolprostate cancer cellprostate cancer progressionresistance mechanismtherapy resistanttreatment choicetumortumorigenesis
中文摘要
摘要
英文摘要
Abstract
Prostate cancer is one of the leading causes of cancer-related mortality in American men, second only
to lung cancer. Primary and advanced prostate cancers respond to androgen ablation therapy initially, which is
followed by progression to castration resistance within a short frame of time for many patients. Recently a
second-generation anti-androgen, enzalutamide has been approved by the FDA for the treatment of
chemotherapy-naïve as well as post-chemotherapy prostate cancers. But innate and acquired resistance to
enzalutamide treatment has been observed in the clinic and the mechanisms are still being studied. Use of
PSA as a biomarker does not predict the possible outcome of patients with respect to development of
resistance. Identification of biomarkers which facilitate risk assessment and predict which patients will respond
to treatment would better inform treatment choices and improve patient care. MicroRNAs may serve as ideal
non-invasive biomarkers due to their specificity and proportionality to disease development. MicroRNAs can be
analyzed in biofluids such as blood, sera, urine, plasma etc., and in exosomes isolated from these biofluids.
Our preliminary data show that miR-Let-7c is downregulated in enzalutamide-resistant prostate cancer, while
its master regulator, Lin28 is upregulated. We also show that both Let-7c and Lin28 can be reliably measured
in exosomes derived from human prostate cancer cells. Hence, we hypothesize that the alteration of the Let-
7c:Lin28 ratio in tumor-derived exosomes may serve as a potential predictor of therapy-resistance in prostate
cancer.
In aim 1, we will validate preliminary data in a systematic study involving the measurement of
expression levels of Let-7c and Lin28 in prostate cancer samples and tumor-derived exosomes from the UC
Davis Cancer Center Biorepository and the Prostate Cancer Biorepository Network (PCBN) using quantitative
real-time PCR. In aim 2, we will develop bioassays to assess the Let-7c:Lin28 status in tumor-derived
exosomes from xenografts of human prostate cancer cells. These bioassays will be validated in a limited
cohort human study using blood samples from patients with enzalutamide-treated prostate cancer. Blood
samples will be collected at 4 time points during the treatment of patients with enzalutamide and prostate-
derived exosomes will be isolated. The ability of the ratio of Let-7c:Lin28 to predict the development of
resistance to enzalutamide will be evaluated following the measurement of Let-7c and Lin28 levels in
exosomes using quantitative real-time PCR. These studies will provide a rationale for the assessment of the
ability of the ratio of Let-7c:Lin28 to predict whether they will respond to enzalutamide in a larger cohort of
patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文